Tu1302 Anti-TNF-α Induction Regimen Modulates Gut Microbiota Molecular Composition While Inducing Clinical Response in Crohn's Disease Patients: Toward a Personalized Medicine

Scaldaferri, Franco; Gerardi, Viviana; Pecere, Silvia; Petito, Valentina; Lopetuso, Loris Riccardo; Zambrano, Daniela; Schiavoni, Elisa; D’Ambrosio, Daria; Agostini, Angelica Di; Laterza, Lucrezia; Sterbini, Francesco Paroni; Franceschi, Francesco; Gaetani, Eleonora; Cammarota, Giovanni; Sanguinetti, Maurizio; Masucci, Luca; Gasbarrini, Antonio

doi:10.1016/s0016-5085(15)32890-0

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, such an improvement has not been found to consistently correlate with treatment efficacy. It has also been shown that longitudinal changes in microbiota composition correlate with response to anti-TNF therapy: in particular, an increase in the Firmicutes phylum (most notably, F. prausnitzii) has been observed in responders [ 131 , 133 , 140 ].…”

Section: Gut Microbiotamentioning

confidence: 99%

Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases

Privitera

Pugliese

Rapaccini

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD) are chronic conditions that primarily affect the gastrointestinal tract, with a complex pathogenesis; they are characterized by a significant heterogeneity of clinical presentations and of inflammatory pathways that sustain intestinal damage. After the introduction of the first biological therapies, the pipeline of therapies for IBD has been constantly expanding, and a significant number of new molecules is expected in the next few years. Evidence from clinical trials and real-life experiences has taught us that up to 40% of patients do not respond to a specific drug. Unfortunately, to date, clinicians lack a valid tool that can predict each patient’s response to therapies and that could help them in choosing what drug to administer. Several candidate biomarkers have been investigated so far, with conflicting results: clinical, genetic, immunological, pharmacokinetic and microbial markers have been tested, but no ideal marker has been identified so far. Based on recent evidence, multiparametric models seemingly hold the greatest potential for predicting response to therapy. In this narrative review, we aim to summarize the current knowledge on predictors and early markers of response to biological therapies in IBD.

show abstract

Section: Gut Microbiotamentioning

confidence: 99%

Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases

Privitera

Pugliese

Rapaccini

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Few studies have evaluated the variability in gut microbiota after anti-TNF therapy in adult patients with IBD [14,[21][22][23][26][27][28][29][30]. However, from the results obtained it is not possible to determine the exact percentage of expected variability.…”

Section: Sample Size Considerationsmentioning

confidence: 99%

Evaluation of Changes in Gut Microbiota in Patients with Crohn’s Disease after Anti-Tnfα Treatment: Prospective Multicenter Observational Study

Sanchis-Artero

Martínez-Blanch

Manresa-Vera

et al. 2020

IJERPH

View full text Add to dashboard Cite

Background: Crohn’s disease is believed to result from the interaction between genetic susceptibility, environmental factors and gut microbiota, leading to an aberrant immune response. The objectives of this study are to evaluate the qualitative and quantitative changes in the microbiota of patients with Crohn’s disease after six months of anti-tumor-necrosis factor (anti-TNFα) (infliximab or adalimumab) treatment and to determine whether these changes lead to the recovery of normal microbiota when compared to a control group of healthy subjects. In addition, we will evaluate the potential role of the Faecalibacterium prausnitzii/Escherichia coli and Faecalibacterium prausnitzii/Clostridium coccoides ratios as indicators of therapeutic response to anti-TNFα drugs. Methods/Design: This prospective multicenter observational study will comprise a total of 88 subjects: 44 patients with Crohn’s disease scheduled to start anti-TNFα treatment as described in the drug specifications to control the disease and 44 healthy individuals who share the same lifestyle and eating habits. The presence of inflammatory activity will be determined by the Harvey-Bradshaw index, analytical parameters in blood, including C-reactive protein, and fecal calprotectin levels at commencement of the study, at three months and at six months, allowing the classification of patients into responders and non-responders. Microbiota composition and the quantitative relationship between Faecalibacterium prausnitzii and Escherichia coli and between Faecalibacterium prausnitzii and Clostridium coccoides group as indicators of dysbiosis will be studied at inclusion and six months after initiation of treatment using ultra sequencing with Illumina technology and comparative bioinformatics analysis for the former relationship, and digital droplet PCR using stool samples for the latter. Upon inclusion, patients will complete a survey of dietary intake for the three days prior to stool collection, which will be repeated six months later in a second collection to minimize dietary bias. Discussion: In this study, massive sequencing, a reliable new tool, will be applied to identify early biomarkers of response to anti-TNF treatment in patients with Crohn’s disease to improve clinical management of these patients, reduce morbidity rates and improve efficiency.

show abstract

The influence of biologics on the microbiome in immune-mediated inflammatory diseases: A systematic review

Ruszkowski

Daca

Szewczyk

et al. 2021

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Tu1302 Anti-TNF-α Induction Regimen Modulates Gut Microbiota Molecular Composition While Inducing Clinical Response in Crohn's Disease Patients: Toward a Personalized Medicine

Cited by 5 publications

References 0 publications

Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases

Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases

Evaluation of Changes in Gut Microbiota in Patients with Crohn’s Disease after Anti-Tnfα Treatment: Prospective Multicenter Observational Study

The influence of biologics on the microbiome in immune-mediated inflammatory diseases: A systematic review

Contact Info

Product

Resources

About